From the young model to the aging retiree, from the elite athlete to the weekend warrior, to the immune-compromised patient and the patient with other co-morbidities, clinicians continue to search for ways to control pain and accelerate the healing process. Utilizing various therapies has proven to have many profound benefits; not the least of which includes overall superior outcomes.

Dawning on the horizon of medical advancements, these therapies hold the potent healing potential whose benefits have the power to span disciplines as diverse as hair restoration and orthopedics. These therapies harness the power and versatility of the human body to regenerate damaged skin accelerate healing, reactivate hair follicles, heal wounds alleviate pain.

 

 

Available Treatments

RESToR is a minimally manipulated allograft, derived from the umbilical cord tissue layer of Wharton’s Jelly and processed to maximize concentration. RESToR is for homologous use and is intended to enhance the body’s natural ability to heal.

Why RESToR

RESToR works by secreting powerful bioactive molecules. RESToR contains a network of scaffolding proteins, growth factors, cytokines, mesenchymal stem cells and multiple other components needed to enhance the body’s natural ability to heal.

RESToR umbilical cord tissues lack MHC-II and are therefore hypo-immunogenic, consequently there is minimal risk of an allergic reaction for the recipient.

RESToR has a strong anti-inflammatory effect reducing the expression of inflammatory cytokines. 2

RESToR has a higher proliferation rate when compared to autologous tissue such as adipose or bone marrow.

RESToR is less invasive when compared to other forms of regenerative medicine such as bone marrow and adipose tissue extraction; this results in less pain and rehabilitation time for the patient.

RESToR is recovered from healthy, carefully screened mothers at the time of a scheduled cesarean section. All protocols are in accordance with the FDA and American Association of Tissue Banks (AATB) regulations and standards.

RESToR is regulated as a human cell tissue product (HCT/P) under 21 CFR Part 127 and Section 361 of the Public Service Health Act.

 

 

 

RENuE is a human tissue allograft derived from the umbilical cord and is intended for homologous use to supplement or replace damaged or inadequate connective tissue.
The cushioning and structural support elements from the Wharton’s Jelly consist of a network of structural proteins, cytokines, chemokines and growth factors. Wharton’s Jelly also has a much higher concentration of hyaluronic acid, cytokines and growth factors when compared to Amniotic fluid, up to 50 times more. Hyaluronic acid is the key factor in the viscoelastic properties in synovial fluid and joints.

Why RENuE

RENuE is less invasive when compared to others forms of regenerative medicine such as bone marrow aspirate and adipose tissue extraction. This results in less pain and rehabilitation time for the patient.

• Compared to amniotic fluid therapy, RENuE contains higher concentrations of hyaluronic acid, peptides and growth factors.

• Higher concentrations of growth factors in RENuE act as an anti-inflammatory and have been shown to prevent cell death. *

RENuE is recovered from healthy, carefully screened mothers at the time of a scheduled cesarean section. All protocols are in accordance with the FDA and American Association of Tissue Banks (AATB) regulations and standards. RENuE is regulated as a human cell, tissue, or cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act.

 

 

 

RELeV is a minimally manipulated allograft fluid with proven regenerative potential. The components in amnion are intended to maintain regenerative tissue processes.
Amniotic fluid contains growth factors, carbohydrates, proteins, amino acids and a multitude of essential molecules that are needed for tissue protection.

Why RELeV

RELeV is intended to help with inflammation and to enhance the healing process.

RELeV is immune-privileged; the risk of rejection is extremely rare.

• For in-office procedures there is minimal, if any, down time after treatment.

RELeV is typically a one-time treatment compared to corticosteroids which mask the pain by shutting down the body’s nerves in a specific area. Relief with steroids does begin right away but it does not last and there are significant side-effects from long term use.

RELeV is recovered from healthy, carefully screened mothers at the time of cesarean section. All protocols are in accordance with the FDA and the American Association of Tissue Banks (AATB) regulations and standards. RELeV is regulated as a human cell, tissue, or cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act.

 

 

 

 

REViV is a minimally manipulated human tissue allograft derived from the amniotic fluid and the extracellular matrix of the amniotic membrane. REViV is for homologous use and is intended to regulate and maintain tissue regenerative processes.
The extracellular matrix of REViV contains a high concentration of cellular scaffolding, cytokines, growth factors and proteins. The extracellular matrix (ECM) is a collection of extracellular molecules that provide the structural support needed for surrounding cells.
Amniotic ECM is comprised of collagens, multi-adhesive glycoproteins, elastic, glycosaminoglycans, growth factors and cytokines.

Why REViV

REViV components are intended to reduce inflammation and continue the healing process, improving, or in some cases, eliminating your pain.

REViV is immune-privileged; the risk of rejection is extremely rare.

• For in-office procedures there is minimal, if any, down time after treatment.

REViV is typically a one-time treatment compared to corticosteroids which mask the pain by shutting down the body’s nerves in a specific area. Relief with steroids does begin right away but it does not last and there are significant side-effects from long term use.

REViV is recovered from healthy, carefully screened mothers at the time of cesarean section.
All protocols are in accordance with the FDA and the American Association of Tissue Banks (AATB) regulations and standards. REViV is regulated as a human cell, tissue, or cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act.